ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $208,565 | -22.6% | 7,762 | +2.8% | 0.00% | -100.0% |
| Q2 2023 | $269,304 | +22.8% | 7,552 | -12.6% | 0.00% | 0.0% |
| Q1 2023 | $219,380 | -34.0% | 8,637 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $332,611 | +42.8% | 8,637 | +22.5% | 0.00% | 0.0% |
| Q3 2022 | $233,000 | -6.8% | 7,053 | -0.5% | 0.00% | 0.0% |
| Q2 2022 | $250,000 | +25.6% | 7,088 | +64.1% | 0.00% | 0.0% |
| Q1 2022 | $199,000 | -29.9% | 4,319 | +6.2% | 0.00% | 0.0% |
| Q4 2021 | $284,000 | +5.2% | 4,065 | -6.1% | 0.00% | 0.0% |
| Q3 2021 | $270,000 | -24.6% | 4,328 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $358,000 | +0.3% | 4,328 | -19.7% | 0.00% | 0.0% |
| Q1 2021 | $357,000 | +31.7% | 5,388 | +52.5% | 0.00% | 0.0% |
| Q4 2020 | $271,000 | +19.4% | 3,532 | -33.1% | 0.00% | 0.0% |
| Q3 2020 | $227,000 | +0.9% | 5,283 | +1.5% | 0.00% | -33.3% |
| Q2 2020 | $225,000 | – | 5,207 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |